個別化医療バイオマーカーの市場規模、シェア、動向分析レポート：用途別、適応症別、地域別、セグメント予測、2025年～2030年

個別化医療バイオマーカー市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の個別化医療バイオマーカーの市場規模は、2025年から2030年にかけて13.6%のCAGRを記録し、2030年までに471億6,000万米ドルに達すると推定されています。

この成長は、認知度の上昇、予後予測の重要性、投与量の選択に起因しています。さらに、個別化医療バイオマーカーは、患者を選択し、適切な患者に適切な治療を提供するために不可欠なツールとして機能し、個別化医療バイオマーカーの需要をさらに促進しています。

バイオマーカーは、診断予測治療結果の改善や治療方針の決定に活用できるユニークな分析物です。バイオマーカーは個別化医療に不可欠です。患者の予後を改善するためのバイオマーカーの利用は臨床試験で盛んであり、臨床での利用は急速に拡大しています。バイオマーカーを利用した個別化医療の開発により、すべての患者にとって効果的で安全な治療法の創出が期待されます。これは、がんのような慢性疾患の進行段階にある患者にとって大きな安心材料となり、市場の成長をさらに後押しします。例えば、2022年8月には、ペムブロリズマブ治療の対象となる進行がん患者の同定に使用される初のIHCベースのアッセイであるVENTANA MMR RxDx PanelがFDAに承認されました。

早期発見/スクリーニングバイオマーカーは、治療前の患者集団における疾患の転帰を予測します。また、治療に反応しやすい患者を選択することで、臨床試験の充実にも役立ちます。例えば、Oncotype DxはGenomic Healthが開発した診断検査です。この検査は21の遺伝子を調べ、初回治療後の患者の乳がん再発の可能性を予測するのに役立ちます。2022年4月、ASCOのガイドラインが更新され、早期乳がん患者に対してOncotype DX検査の使用が推奨され、治療決定の指針となりました。

さらに、バイオマーカーは、健康状態の発生を予測するのに役立つ予測と予後の有用性のために使用されます。例えば、前立腺特異抗原は前立腺がん患者の生存予測に用いられます。CRPは、乳がんの無病生存率の予測や心血管障害の危険因子として用いられます。血清LDHは転移性脳腫瘍の生存予測に役立ちます。同様に、CA125は子宮がん患者の転移性疾患の予測に役立ちます。

さらに、個別化医療バイオマーカー業界で事業を展開する主要企業は、幅広い用途に使用できる製品の拡大と上市に注力しています。例えば、2021年10月、Agilent Technologies Inc.は、乳がんの再発リスクが高い患者を特定するためのAgilent Ki-67 IHC MIB-1 pharmDx（Dako Omnis）のFDA承認を取得しました。

個別化医療バイオマーカー市場レポートハイライト

• 用途別では、早期発見/スクリーニング分野が、患者への早期治療の必要性からCAGR最速の成長が見込まれます。
• 適応症別では、がんの有病率の上昇とFDA認可のがんの個別化バイオマーカー検査が広く利用可能であることから、2024年にはがん分野が最大の市場シェアを占めました。
• 北米は、ヘルスケアインフラの改善、対象疾患の有病率の上昇、バイオマーカーのイノベーションに対する政府資金の増加により、最大の市場シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 個別化医療バイオマーカー市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 個別化医療バイオマーカー市場分析ツール
  • 業界分析 - ポーターのファイブフォース分析
  • PESTEL分析

第4章 個別化医療バイオマーカー市場：用途の推定・動向分析

• セグメントダッシュボード
• 個別化医療バイオマーカー市場：適応症の変動分析
• 個別化医療バイオマーカー市場展望：適応症別
• 市場規模・予測と動向分析、2018年～2030年
• 早期発見・スクリーニング
• 診断
• 治療の選択
• 監視

第5章 個別化医療バイオマーカー市場：適応症の推定・動向分析

• セグメントダッシュボード
• 個別化医療バイオマーカー市場：バイオマーカーの変動分析
• 個別化医療バイオマーカー市場：バイオマーカー別の展望
• 市場規模・予測と動向分析、2018年～2030年
• 腫瘍学
• 神経学
• 糖尿病
• 自己免疫疾患
• 心臓病学
• その他

第6章 個別化医療バイオマーカー市場：地域の推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年～2030年：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 企業分類
• 最近の動向と影響分析、主要市場参入企業別
• 企業市場シェア分析、2024年
• 会社概要
  • Laboratory Corporation of America Holding
  • Quest Diagnostics Incorporated
  • Agilent Technologies, Inc
  • Genome Medical, Inc
  • Thermo Fisher Scientific, Inc
  • Coriell Life Sciences
  • NeoGenomics Laboratories
  • FOUNDATION MEDICINE, INC
  • Illumina, Inc
  • Guardant Health

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 4 Global personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 5 North America personalized medicine biomarkers, by region, 2018 - 2030 (USD Billion)
• Table 6 North America personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 7 North America personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 8 U.S. personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 9 U.S. personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 10 Canada personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 11 Canada personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 12 Mexico personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 13 Mexico personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 14 Europe personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
• Table 15 Europe personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 16 Europe personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 17 UK personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 18 UK personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 19 Germany personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 20 Germany personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
• Table 21 France personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 22 France personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
• Table 23 Italy personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 24 Italy personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 25 Spain personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 26 Spain personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 27 Denmark personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 28 Denmark personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
• Table 29 Norway personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 30 Norway personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 31 Sweden personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 32 Sweden personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 33 Asia Pacific personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
• Table 34 Asia Pacific personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 35 Asia Pacific personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 36 Japan personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 37 Japan personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 38 China personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 39 China personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
• Table 40 India personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 41 India personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 42 Australia personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 43 Australia personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 44 South Korea personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 45 South Korea personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 46 Thailand personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 47 Thailand personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 48 Latin America personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
• Table 49 Latin America personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 50 Latin America personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 51 Brazil personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 52 Brazil personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 53 Argentina personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 54 Argentina personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 55 Middle East & Africa personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
• Table 56 Middle East & Africa personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 57 Middle East & Africa personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 58 South Africa personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 59 South Africa personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 60 Saudi Arabia personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 61 Saudi Arabia personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 62 UAE personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 63 UAE personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
• Table 64 Kuwait personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
• Table 65 Kuwait personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Information procurement
• Fig. 2 Primary research pattern
• Fig. 3 Market research approaches
• Fig. 4 Value chain-based sizing & forecasting
• Fig. 5 Market formulation & validation
• Fig. 6 Personalized medicine biomarkers market segmentation
• Fig. 7 Market driver analysis (current & future impact)
• Fig. 8 Market restraint analysis (current & future impact)
• Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 10 Porter's five forces analysis
• Fig. 11 Personalized medicine biomarkers market: Application outlook and key takeaways
• Fig. 12 Early detection/screening market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 13 Diagnosis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 14 Treatment selection market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 15 Monitoring circulating biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 16 Personalized medicine biomarkers market: Indication outlook and key takeaways
• Fig. 17 Personalized medicine biomarkers market: Indication movement analysis
• Fig. 18 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Autoimmune diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Personalized Medicine Biomarkers Market: Regional outlook and key takeaways
• Fig. 25 Breast cancer liquid biopsy: Regional movement analysis
• Fig. 26 Personalized medicine biomarkers market: regional key takeaways (USD Billion)
• Fig. 27 Personalized medicine biomarkers market: regional outlook, 2023 & 2030 (USD Billion)
• Fig. 28 North America personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 29 U.S. personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 30 Canada personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 31 Mexico personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 32 Europe personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 33 UK personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 34 Germany personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 35 France personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 36 Spain personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 37 Italy personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 38 Norway personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 39 Denmark personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 40 Sweden personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 41 Asia Pacific personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 42 China personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 43 Japan personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 44 India personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 45 South Korea personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 46 Australia personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 47 Thailand personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 48 Latin America personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 49 Brazil personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 50 Argentina personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 51 Middle East and Africa personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 52 South Africa personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 53 Saudi Arabia personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 54 UAE personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 55 Kuwait personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 56 List of key emerging company's/technology disruptors/innovators

Personalized Medicine Biomarkers Market Growth & Trends:

The global personalized medicine biomarkers market size is estimated to reach USD 47.16 billion by 2030, registering a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising awareness, importance of predicting prognosis, and selection of dose. Moreover, personalized medicine biomarkers serve as an essential tool for the selection of patients and providing the right treatment to the right patient further propelling the demand for personalized medicine biomarkers.

Biomarkers are unique analytes that can be utilized to improve diagnosis forecast treatment outcomes and direct treatment decisions. They are crucial to personalized medicine. The increased usage of biomarkers to enhance patient outcomes is popular in clinical trials, and its use in clinical practice is expanding quickly. The development of personalized medicines using biomarkers is expected to create effective and safe therapies for every patient. This is a major relief for patients at advanced stages of chronic diseases like cancer, which further drives the market growth. For instance, in August 2022, VENTANA MMR RxDx Panel, an FDA approved first IHC-based assay used for the identification of patients with advanced cancer that is Pembrolizumab treatment eligible.

Early detection/screening biomarkers predict the outcome of disease in patient population prior to therapy. It can also help enrich clinical trials by helping choose patients more likely to respond to treatment. For instance, Oncotype Dx is a diagnostic test developed by Genomic Health, Inc. This test examines 21 genes and helps predict the likelihood of reoccurrence of breast cancer in a patient after initial treatment. In April 2022, updated ASCO guidelines recommended the usage of the Oncotype DX test for breast cancer patients at early stages to guide treatment decisions.

Moreover, biomarkers are used for their predictive and prognostic utility that helps predict the occurrence of a health condition. For instance, the prostate-specific antigen is used to predict the survival of patients with prostate cancer. CRP is used to predict disease-free survival in breast cancer and as a risk factor in cardiovascular disorders. Serum LDH helps predict survival in case of metastatic brain tumors. Similarly, CA125 helps predict metastatic diseases in patients with uterine carcinoma.

Furthermore, key players operating in the personalized medicine biomarkers industry are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in October 2021, Agilent Technologies Inc. received FDA approval for Agilent Ki-67 IHC MIB-1 pharmDx (Dako Omnis), for the identification of patients with a high risk of breast cancer recurrence.

Personalized Medicine Biomarkers Market Report Highlights:

• Based on application, the early detection/screening segment is expected to grow at the fastest CAGR owing to the need to provide early treatment to patients.
• By indication, the oncology segment held the largest market share in 2024, owing to the rising prevalence of cancer and the wide availability of FDA-approved personalized biomarkers tests for cancer
• North America held the largest market share attributable to the presence of improved healthcare infrastructure, rising prevalence of target diseases, and increasing government funding for innovation in biomarkers.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Application
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. Indication outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Personalized Medicine Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Rising awareness and importance of predicting prognosis and selection of dose
    • 3.2.1.3. Need to provide early diagnosis and treatment
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory & reimbursement hurdles
• 3.3. Personalized Medicine Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Personalized Medicine Biomarkers Market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Personalized Medicine Biomarkers Market: Indication Movement Analysis
• 4.3. Personalized Medicine Biomarkers Market by Indication Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Early Detection/Screening
  • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.6. Diagnosis
  • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.7. Treatment Selection
  • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.8. Monitoring
  • 4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Personalized Medicine Biomarkers Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Personalized Medicine Biomarkers Market: Biomarker Movement Analysis
• 5.3. Personalized Medicine Biomarkers Market by Biomarker Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Oncology
  • 5.5.1. By Type Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.1.1. Breast Cancer
      • 5.5.1.1.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.1.2. Lung Cancer
      • 5.5.1.2.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.1.3. Colon Cancer
      • 5.5.1.3.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.1.4. Others
      • 5.5.1.4.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.5.2. By Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.2.1. Circulating Tumor Cells
      • 5.5.2.1.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.2.2. Circulating Cell-free DNA
      • 5.5.2.2.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.2.3. Extracellular Vesicles
      • 5.5.2.3.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.2.4. Other Circulating Biomarkers
      • 5.5.2.4.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6. Neurology
  • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.7. Diabetes
  • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.8. Autoimmune Diseases
  • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.9. Cardiology
  • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Personalized Medicine Biomarkers Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Company Market Share Analysis, 2024
• 7.4. Company overview
  • 7.4.1. Laboratory Corporation of America Holding
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Quest Diagnostics Incorporated
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Agilent Technologies, Inc
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Genome Medical, Inc
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Thermo Fisher Scientific, Inc
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Coriell Life Sciences
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. NeoGenomics Laboratories
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. FOUNDATION MEDICINE, INC
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Illumina, Inc
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Guardant Health
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives